support@mellalta.com   +1 (304) 306-0723

Intellia’s CRISPER/Cas9 and Teneobio’s UniAb technology providing a new dimension to cell therapy

Tenebio Strategy 2021

A clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), Teneobio and a leading genome editing company focused on developing proprietary curative therapeutics using the CRISPR/Cas9 system i.e Intellia therapeutics […]

Read More

Get In Touch

Let's keep the conversation going